WS635 Oral Compound for Direct Wound Healing Promotion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral drugs for wound care lack effectiveness in directly promoting wound healing, and existing treatments primarily focus on auxiliary aspects such as pain management and infection relief, with a need for compounds that can accelerate the healing process.
Innovation Solution
The compound WS635, a non-immunosuppressive derivative of cyclosporin A, is administered orally to promote angiogenesis and wound healing by inhibiting Cyclophilin D, demonstrating efficacy in reducing wound area and enhancing healing rates in rats.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral drugs are used for wound care, then ease of administration is improved, but effectiveness in directly promoting wound healing deteriorates
Solution Approach 1:
The patent modifies the chemical structure of cyclosporin A to create WS635, a non-immunosuppressive derivative that specifically targets Cyclophilin D. This parameter change in molecular structure enables the compound to cross the blood-brain barrier and activate angiogenesis pathways orally, transforming an ineffective oral administration route into an effective therapeutic approach for wound healing.
Solution Approach 2:
WS635 acts as an intermediary substance that bridges the gap between oral administration and wound healing promotion. By inhibiting Cyclophilin D, it serves as a mediator that triggers downstream angiogenic effects, enabling indirect but effective wound healing promotion through a simple oral dosage form.
2Speed
If growth factors are injected to promote wound healing, then wound healing speed is improved, but complexity of treatment and potential side effects worsen
Solution Approach 1:
Instead of using complex, expensive growth factor injections, the patent employs WS635, a small molecule compound that can be administered orally as a simple tablet or capsule. This disposable-like approach replaces complex biological preparations with a straightforward chemical compound that achieves similar or superior healing effects with much simpler administration.
Solution Approach 2:
The patent extracts the essential therapeutic activity from complex growth factor preparations and isolates it into the specific mechanism of Cyclophilin D inhibition. By taking out the core functional element (angiogenesis promotion) and delivering it through WS635, the treatment becomes simpler while maintaining effectiveness.
3Ease of operation
If existing oral drugs are used for wound care, then ease of use is improved, but lack of direct healing promotion worsens
Solution Approach 1:
WS635 exhibits multi-functionality by simultaneously providing pain relief, infection prevention, and direct wound healing promotion through a single oral compound. This universal approach replaces the need for multiple separate medications, making the treatment easier to use while significantly improving wound healing productivity through direct mechanistic action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
WS635 significantly promotes wound healing by increasing angiogenesis and reducing wound area, with a NOAEL dose of 80mg/kg/day showing minimal toxicity and improved stability, comparable to recombinant bovine basic fibroblast growth factor.
Implementation Method 1
WS635 is a non-immunosuppressive derivative of CsA (cyclosporin A) double-substituted at the 3 and 4 positions that binded to CypD (Cyclophilin D) to inhibit the opening of mPTP
Implementation Method 2
the vascular endothelial growth factor, fibroblast growth factor and insulin growth factor increased in the wound where the growth factor was injected, which promoted the growth of epithelial cells and angiogenesis
Implementation Method 3
The proliferation stage is characterized by the formation of granulation tissue, which is composed of newly formed blood vessels, immune cells and fibroblasts
Implementation Method 4
In the process of scar tissue formation, fibroblasts in the dermis and epidermis deposit new extracellular matrix to strengthen the repaired tissue
Data Source
Figure 1~2
AI summary
The present invention relates to a method of inducing or accelerating a healing process of wound in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof.